Medication overuse headache in Australia: a call for multidisciplinary efforts at prevention and treatment

Richard J Stark, Treasure McGuire and Mieke L van Driel
Med J Aust 2016; 205 (6): . || doi: 10.5694/mja16.00492
Published online: 19 September 2016

Medication overuse headache (MOH)1 is prevalent, under-recognised and potentially treatable or avoidable using a multidisciplinary approach.

  • 1 Neurology Service, Alfred Health, Melbourne, VIC
  • 2 Department of Medicine, Monash University, Melbourne, VIC
  • 3 University of Queensland, Brisbane, QLD
  • 4 Bond University, Gold Coast, QLD



We thank Esther Anderson of In Vivo Communications for her assistance in medical writing.

Competing interests:

Richard Stark has received lecture and consulting fees from Allergan, MSD, AbbVie and SciGen, and from In Vivo Academy relating to a Pfizer-sponsored project. He has also undertaken clinical trials for Allergan.

  • 1. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd ed. (beta version). Cephalalgia 2013; 33: 629-808.
  • 2. Williams D. Medication overuse headache. Aust Prescr 2005; 28: 143-145.
  • 3. Therapeutic Goods Administration. Proposal for the re-scheduling of codeine products. Canberra: Australian Government, Department of Health, 2015. (accessed Apr 2016).
  • 4. Stark R, Hutton E. Chronic migraine and other types of chronic daily headache. Medicine Today 2013; 14: 29-35.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.